1. ALLA AKTIER
  2. NYHETER
  3. XBRANE BIOPHARMA

Xbrane Biopharma

Nyheter Xbrane Biopharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Xbrane AB (publ) today announces that the company's CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.

MAR

Xbrane Biopharma AB today announces that Chief Financial Officer & Head of IR Anette Lindqvist has informed CEO Marin Åmark of her intention to scale back her operational work and thereby leave her position as CFO during the spring of 2025. Anette has been CFO for Xbrane since 2021 and will remain in her role until a replacement is secured. The recruitment process for a new CFO will begin immediately.

"I would like to thank Anette for her work in recent years and wish her the best of luck with her plans to have more time for other things. The recruitment process for a new CFO will begin immediately and I feel confident that Anette, together with her competent employees, will guarantee a smooth handover process," says Martin Åmark, CEO.

"Xbrane is a fantastic company with very talented and knowledgeable colleagues with whom it has been a pleasure to work and whom I will miss a lot, while I look forward to having more time for other interests," says Anette Lindqvist CFO.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-26 17:20 CET.

Attachments

Xbrane AB (publ) today announces that the company's CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.

Datum 2024-11-26, kl 17:20
Källa MFN
Bifogade filer
Xbrane AB (publ) today announces that the company's CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.